 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Selank" – news ·newspapers ·books ·scholar ·JSTOR(December 2010) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| Other names | Selanc;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline |
| Routes of administration | Nasal muscosa, IV |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C33H57N11O9 |
| Molar mass | 751.887 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Selank (Russian: Cеланк) is anootropicanxiolyticpeptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with thesequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of the humantuftsin. It was initially developed to modulate brain activity and the immune system and may help regulate neurotransmitters like serotonin and dopamine to promote cognitive stability and emotional balance.[1]
Selank is a synthetic analogue of the immunomodulatory peptidetuftsin; as such, it mimics many of its effects. It has been shown to modulate the expression ofInterleukin-6 (IL-6) and affect the balance ofT helper cellcytokines.[2] It has been shown to influence the concentration ofmonoamine neurotransmitters[3] and induce metabolism ofserotonin.[4][5] Selank has also been found to rapidly elevate the expression ofbrain-derived neurotrophic factor (BDNF) in thehippocampus of rats.[6]
Selank, as well as a related peptide drug,Semax, have been found to inhibitenzymes involved in the degradation ofenkephalins and otherendogenous regulatorypeptides, and this action may be involved in their effects.[7] It has also been found to affect the activity ofcarboxypeptidase H andphenylmethylsulfonylfluoride-inhibitedcarboxypeptidase in rat nervous system tissue.[8]
Selank has been found to produceantidepressant-like effects inanimal models ofdepression andanhedonia.[9]
In clinical studies, Selank has been investigated for its potential effects on cognitive function and anxiety.[2] It has also been compared with traditional anxiolytic drugs such asbenzodiazepines andbarbiturates.[10]
Selank is closely related to another nootropic drug,Semax, also developed by the Institute of Molecular Genetics in Russia. This drug is currently available in Russian and Ukrainian pharmacies.[11]
As with alllyophilized peptides, it needs refrigeration to remain stable within sterile water solutions, such as bacteriostatic water concentrations.
